Novartis AG reaffirmed its excitement about the commercial potential of the chimeric antigen receptor T cell (CAR-T) therapy CTL019 during a meet-the-management event at the company's research campus in Cambridge, Mass. May 31.
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
CEO Joe Jimenez told investors the firm is encouraged about the commercial prospects for CAR-T therapy. Lead drug CTL019 made Novartis' list of blockbusters in development after having been left off last year.
More from Strategy
More from Business
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.